p.45 抽出テキスト
Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation 2017; 135: 659-670. PMID: 27881565 187. Uchiyama S, Ishizuka N, Shimada K, et al. JPPP Study Group. Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. Stroke 2016; 47: 1605-1611. PMID: 27165949 188. Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb 2018; 25: 846-984. PMID: 30135334 189. Lewis CE, Fine LJ, et al. SPRINT Research Group. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2021; 384: 1921-1930. PMID: 34010531 190. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-39. PMID: 30424892 191. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7: 776-785. PMID: 31422062 192. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573. PMID: 33441402 193. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323. PMID: 31497854 194. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes―2021. Diabetes Care 2021; 44 Suppl: S125-S150. PMID: 33298421 195. Bhatt DL, Steg PG, Miller M, et al. REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019; 380: 11-22. PMID: 30415628 196. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020; 324: 2268-2280. PMID: 33190147 197. Virani SS, Nambi V, Ballantyne CM. Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH. Eur Heart J Cardiovasc Pharmacother 2021; 7: e7e8. PMID: 33537734 198. Bouabdallaoui N, Tardif JC, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J 2020; 41: 4092-4099. PMID: 32860034 199. Nidorf SM, Fiolet ATL, Mosterd A, et al. LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383: 1838-1847. PMID: 32865380 200. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: A statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 1694- 1740. PMID: 11581152 201. Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016: CD001800. PMID: 26730878 202. Fulcher J, O’Connell R, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397-1405. PMID: 25579834 203. Baigent C, Blackwell L, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860. PMID: 19482214 204. Frye RL, August P, et al. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515. PMID: 19502645 205. Velazquez EJ, Lee KL, Deja MA, et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364: 1607-1616. PMID: 21463150 206. De Bruyne B, Pijls NH, Kalesan B, et al. FAME 2 Trial Investiga- tors. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012; 367: 991-1001. PMID: 22924638 207. Dumaine RL, Montalescot G, Steg PG, et al. REACH Registry In- vestigators. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J 2009; 158: 141-148. PMID: 19540404 208. Ducrocq G, Wallace JS, Baron G, et al. REACH Investigators. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 2010; 31: 1257-1265. PMID: 20181681 209. Vidal-Petiot E, Ford I, Greenlaw N, et al. CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388: 2142- 2152. PMID: 27590221 210. Kohsaka S, Fukushima K, Watanabe I, et al. Contemporary Management of Stable Coronary Artery Disease - Implications of the ISCHEMIA Trial. Circ J 2021; 85: 1919-1927. PMID: 34148929 210a. 日本循環器学会,日本心不全学会.2021年 JCS/JHFS ガイドライン フォーカスアップデート版 急性・慢性心不全診療.https:// www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf 211. Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883. PMID: 11907286 212. Garcia MJ, Kwong RY, Scherrer-Crosbie M, et al. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circ Cardiovasc Imaging 2020; 13: e000053. PMID: 32833510 213. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17: 1321-1360. PMID: 27422899 214. Steeds RP, Garbi M, Cardim N, et al. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging 2017; 18: 1191-1204. PMID: 28329307 215. 日本循環器学会 / 日本心不全学会.急性・慢性心不全診療ガイドライン(2017年改訂版).https://www.j-circ.or.jp/cms/wp-content/ uploads/2017/06/JCS2017_tsutsui_h.pdf 216. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200. PMID: 27206819 217. Daubert C, Gold MR, Abraham WT, et al. REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the RE- VERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009; 54: 1837- 1846. PMID: 19800193 218. Ryan M, Morgan H, Petrie MC, et al. Coronary revascularisation in patients with ischaemic cardiomyopathy. Heart 2021; 107: 612-618. PMID: 33436491 219. Velazquez EJ, Lee KL, Jones RH, et al. STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016; 374: 1511-1520. PMID: 27040723 220. Fox CS, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673. PMID: 23013602 221. Matsushita K, Coresh J, Sang Y, et al. CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3: 514- 525. PMID: 26028594 222. Herzog CA, Natwick T, Li S, et al. Comparative Utilization and Temporal Trends in Cardiac Stress Testing in U.S. Medicare Beneficiaries With and Without Chronic Kidney Disease. JACC Cardiovasc Imaging 2019; 12: 1420-1426. PMID: 29909107 223. Bangalore S. Stress testing in patients with chronic kidney disease: The need for ancillary markers for effective risk stratification and prognosis. J Nucl Cardiol 2016; 23: 570-574. PMID: 26297196 224. Winther S, Svensson M, Jørgensen HS, et al. Diagnostic Perfor-